Ain Shams adipose-derived insulin-producing cells
What it is
A small Egyptian research protocol proposes turning a participant’s fat-derived cells into insulin-producing cells. No outcomes are posted, and the registry’s estimated completion dates have passed without a status update.
Editorial review: . What was checked and what remains uncertain.
Latest dated source in the citation list: 2025-04-30. This is the source’s date, not a new review of every claim.
Trial status, labels and access can change between reviews.
Evidence behind this assessment
Key evidence notes. Study results, product eligibility and access answer different questions.
- Who was studied?
- Study populations and analysis groups vary. Product age limits alone do not describe who was studied.See the linked studies and their populations →
- Benefit or performance
- Insulin independence: The protocol proposes measuring insulin production; it reports no insulin-independence outcome.[1]
- Important harms and treatment burden
- Immunosuppression-free: Autologous cells do not by themselves prove protection from autoimmunity; the public protocol does not establish a drug-free durable graft.[1]
- Approval and country access
- A small Egyptian research protocol proposes turning a participant’s fat-derived cells into insulin-producing cells. No outcomes are posted, and the registry’s estimated completion dates have passed without a status update.Approval, trial recruitment, local supply and funding are separate. Check the cited label or access source.
- Follow-up and remaining uncertainty
- Durability: No graft survival or durable clinical benefit has been reported in the registry.[1]
Research status alone does not establish approval, clinical benefit or local availability.
Editorial score: calculation and evidence
A weighted editorial judgment on a 0–100 scale, not a probability of success or a measured treatment effect. Higher criterion scores mean more favorable assessments.
Default calculation: 8 × 30 + 8 × 20 + 15 × 20 + 20 × 10 + 20 × 10 + 12 × 10 = 1220; divide by total weight 100. Unrounded weighted result: 12.2.
The protocol proposes measuring insulin production; it reports no insulin-independence outcome.[1]
Autologous cells do not by themselves prove protection from autoimmunity; the public protocol does not establish a drug-free durable graft.[1]
The protocol includes fat collection by liposuction and either portal-vein or peripheral infusion.[1]
The protocol selects ages 15–18 and excludes other autoimmune or chronic diseases and vascular complications.[1]
The sponsor registers Phase 2/3, but only 20 participants are planned and no outcomes are posted; this is not evidence of pivotal-trial maturity.[1]
The full picture
What this record represents
Ain Shams University proposes collecting a participant's adipose tissue, differentiating mesenchymal cells toward insulin-producing cells, and comparing portal with peripheral delivery. It plans 20 adolescents and lists Phase 2/3. Those are protocol descriptions, not evidence that the cells provide mature, glucose-responsive insulin replacement in people.1
Current uncertainty
The latest update is from April 2025. It still lists recruiting even though estimated primary and final completion dates in 2026 have passed. No results are posted, so present activity and enrolment must be confirmed with the investigators.
The public record does not supply a complete safety dataset, durable engraftment result or convincing insulin-independence evidence. It is also insufficient to establish whether immune protection or immunosuppression would be needed. This entry identifies a specific university protocol, not a purchasable stem-cell treatment or a recommendation to seek one.
Sources
- [1]NCT06951074 — study record · registry · 2025-04-30 — Registry update date; retrieved 16 September 2026. Registry registration is not proof of clinical benefit.